Dr. Maribeth Prewitt Sayre, M.D. Preventive Medicine - Public Health & General Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1335 Galindo St, Concord, CA 94520 Phone: 925-687-4451 Fax: 925-687-4450 |
John Pierce Gunderson, MD Preventive Medicine - Occupational Medicine Medicare: Not Enrolled in Medicare Practice Location: 2231 Galaxy Ct, Concord, CA 94520 Phone: 925-685-7744 Fax: 925-685-0462 |
Carmen Nevarez, MD Preventive Medicine - Public Health & General Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2185 Pacheco St, Concord, CA 94520 Phone: 925-887-5218 Fax: 925-676-2814 |
News Archive
Along with age and injuries, obesity is a leading risk factor for osteoarthritis (OA), a painful and disabling joint disease. While excessive weight can aggravate the toll on almost any joint, obesity has been associated with a higher prevalence of hip OA and an increase in total hip arthroplasty (THA).
The Engineering Research Center for Structured Organic Particulate Systems, based at the Rutgers School of Engineering, and Thermo Fisher Scientific have collaborated to accelerate the university's ongoing research on continuous manufacturing techniques for pharmaceutical discovery.c
A low-cost empowerment program for adolescent girls in Kenyan slums sharply curtails rape and sexual harassment of these girls, who live in an environment where women have low status and are frequently attacked, a large new study shows.
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
› Verified 8 days ago